Cargando…
Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) have completely changed the treatment of cancer, and they also can cause multiple organ immune-related adverse reactions (irAEs). Among them, rheumatic irAE is less common, mainly including inflammatory arthritis, rheumatic myalgia/giant cell arteritis, inflammato...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424376/ https://www.ncbi.nlm.nih.gov/pubmed/32832568 http://dx.doi.org/10.1155/2020/2640273 |
_version_ | 1783570327170711552 |
---|---|
author | Xiao, Yan Zeng, Lin Shen, Qinglin Zhou, Zhiyong Mao, Zhifang Wang, Qin Zhang, Xiquan Li, Yingliang Yao, Weirong |
author_facet | Xiao, Yan Zeng, Lin Shen, Qinglin Zhou, Zhiyong Mao, Zhifang Wang, Qin Zhang, Xiquan Li, Yingliang Yao, Weirong |
author_sort | Xiao, Yan |
collection | PubMed |
description | Immune checkpoint inhibitors (ICIs) have completely changed the treatment of cancer, and they also can cause multiple organ immune-related adverse reactions (irAEs). Among them, rheumatic irAE is less common, mainly including inflammatory arthritis, rheumatic myalgia/giant cell arteritis, inflammatory myopathy, and Sjogren's syndrome. For oncologists, rheumatism is a relatively new field, and early diagnosis and treatment is very important, and we need to work closely with experienced rheumatologists. In this review, we focused on the incidence, clinical characteristics, and treatment strategies of rheumatic irAE. |
format | Online Article Text |
id | pubmed-7424376 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-74243762020-08-20 Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors Xiao, Yan Zeng, Lin Shen, Qinglin Zhou, Zhiyong Mao, Zhifang Wang, Qin Zhang, Xiquan Li, Yingliang Yao, Weirong J Immunol Res Review Article Immune checkpoint inhibitors (ICIs) have completely changed the treatment of cancer, and they also can cause multiple organ immune-related adverse reactions (irAEs). Among them, rheumatic irAE is less common, mainly including inflammatory arthritis, rheumatic myalgia/giant cell arteritis, inflammatory myopathy, and Sjogren's syndrome. For oncologists, rheumatism is a relatively new field, and early diagnosis and treatment is very important, and we need to work closely with experienced rheumatologists. In this review, we focused on the incidence, clinical characteristics, and treatment strategies of rheumatic irAE. Hindawi 2020-08-04 /pmc/articles/PMC7424376/ /pubmed/32832568 http://dx.doi.org/10.1155/2020/2640273 Text en Copyright © 2020 Yan Xiao et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Xiao, Yan Zeng, Lin Shen, Qinglin Zhou, Zhiyong Mao, Zhifang Wang, Qin Zhang, Xiquan Li, Yingliang Yao, Weirong Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors |
title | Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors |
title_full | Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors |
title_fullStr | Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors |
title_full_unstemmed | Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors |
title_short | Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors |
title_sort | diagnosis and treatment of rheumatic adverse events related to immune checkpoint inhibitors |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424376/ https://www.ncbi.nlm.nih.gov/pubmed/32832568 http://dx.doi.org/10.1155/2020/2640273 |
work_keys_str_mv | AT xiaoyan diagnosisandtreatmentofrheumaticadverseeventsrelatedtoimmunecheckpointinhibitors AT zenglin diagnosisandtreatmentofrheumaticadverseeventsrelatedtoimmunecheckpointinhibitors AT shenqinglin diagnosisandtreatmentofrheumaticadverseeventsrelatedtoimmunecheckpointinhibitors AT zhouzhiyong diagnosisandtreatmentofrheumaticadverseeventsrelatedtoimmunecheckpointinhibitors AT maozhifang diagnosisandtreatmentofrheumaticadverseeventsrelatedtoimmunecheckpointinhibitors AT wangqin diagnosisandtreatmentofrheumaticadverseeventsrelatedtoimmunecheckpointinhibitors AT zhangxiquan diagnosisandtreatmentofrheumaticadverseeventsrelatedtoimmunecheckpointinhibitors AT liyingliang diagnosisandtreatmentofrheumaticadverseeventsrelatedtoimmunecheckpointinhibitors AT yaoweirong diagnosisandtreatmentofrheumaticadverseeventsrelatedtoimmunecheckpointinhibitors |